<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04624243</url>
  </required_header>
  <id_info>
    <org_study_id>8189-008</org_study_id>
    <secondary_id>2020-000094-24</secondary_id>
    <secondary_id>MK-8189-008</secondary_id>
    <secondary_id>jRCT2071200096</secondary_id>
    <nct_id>NCT04624243</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)</brief_title>
  <official_title>A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Participants Experiencing an Acute Episode of Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of MK-8189 at a range of&#xD;
      doses (8 mg, 16 mg, and 24 mg once daily) in adult participants who have an acute episode of&#xD;
      schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders 5th Edition&#xD;
      (DSM-5) criteria. The primary hypotheses are the following: (1) MK-8189 24 mg is superior to&#xD;
      placebo in reducing the Week 6 mean change from baseline in Positive and Negative Syndrome&#xD;
      Scale (PANSS) total score (2) MK-8189 16 mg is superior to placebo in reducing the Week 6&#xD;
      mean change from baseline in PANSS total score&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">October 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 10, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Positive and Negative Syndrome Scale (PANSS) total score at Week 6: MK-8189 24 mg, MK-8189 16 mg, or placebo</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>The PANSS assesses the severity of schizophrenia symptoms through a 30-item clinician-rated inventory organized into a positive subscale (7 items), a negative subscale (7 items) and a general psychopathology subscale (16 items). For each item, symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme). The PANSS total score for each participant will be calculated as the sum of the rating assigned to each of the 30 PANSS items and will range from 30 (lowest total score) to 210 (highest total score). Higher scores reflect more severe symptoms of schizophrenia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who experience one or more adverse events (AEs)</measure>
    <time_frame>~Up to Week 14</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporarily associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who discontinue study treatment due to an AE</measure>
    <time_frame>~Up to Week 12</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporarily associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PANSS positive subscale (PSS) score at Week 6: MK-8189 24 mg, MK-8189 16 mg, or placebo</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>The PANSS Positive Subscale (PSS) assesses the severity of schizophrenia symptoms and the PANSS PSS score for each participant will be calculated as the sum of the rating assigned to each of the 7 PSS items and will range from 7 (lowest total score) to 49 (highest total score). Higher scores reflect more severe symptoms of schizophrenia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Clinical Global Impression-Severity of Illness (CGI-S) score at Week 6: MK-8189 24 mg, MK-8189 16 mg, or placebo</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>The CGI-S is a single item 7-point clinician rated scale for assessing the global severity of the participant's illness. CGI-S scores range from 1 (participant normal, not ill) to 7 (participant extremely ill). A decrease in the CGI-S score indicates reduced severity of the participant's illness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weight at Week 12: MK-8189 24 mg, MK-8189 16 mg, or risperidone</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Body weight will be measured using a standardized scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PANSS total score at Week 6: MK-8189 8 mg or placebo</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>The PANSS assesses the severity of schizophrenia symptoms through a 30-item clinician-rated inventory organized into a positive subscale (7 items), a negative subscale (7 items) and a general psychopathology subscale (16 items). For each item, symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme). The PANSS total score for each participant will be calculated as the sum of the rating assigned to each of the 30 PANSS items and will range from 30 (lowest total score) to 210 (highest total score). Higher scores reflect more severe symptoms of schizophrenia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weight at Week 6: MK-8189 24 mg, MK-8189 16 mg, MK-8189 8 mg or placebo</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Body weight will be measured using a standardized scale.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">576</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>MK-8189 8 mg (Acute) - MK-8189 8 mg (Extension)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be treated for a total of 12 weeks. Participants will receive MK-8189 8 mg once daily (QD) in the acute treatment period from Week 1-6 followed by MK-8189 8 mg QD in the extension treatment period from Week 7-12 and participants will simultaneously receive risperidone-matching placebo QD from Week 1-12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-8189 16 mg (Acute) - MK-8189 16 mg (Extension)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be treated for a total of 12 weeks. Participants will receive MK-8189 16 mg QD in the acute treatment period from Week 1-6 followed by MK-8189 16 mg QD in the extension treatment period from Week 7-12 and participants will simultaneously receive risperidone-matching placebo QD from Week 1-12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-8189 24 mg (Acute) - MK-8189 24 mg (Extension)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be treated for a total of 12 weeks. Participants will receive MK-8189 24 mg QD in the acute treatment period from Week 1-6 followed by MK-8189 24 mg QD in the extension treatment period from Week 7-12 and participants will simultaneously receive risperidone-matching placebo QD from Week 1-12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risperidone 6 mg (Acute) - Risperidone 6 mg (Extension)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be treated for a total of 12 weeks. Participants will receive risperidone 6 mg QD in the acute treatment period from Week 1-6 followed by risperidone 6 mg QD in the extension treatment period from Week 7-12 and participants will simultaneously receive MK-8189-matching placebo QD from Week 1-12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to MK-8189 (Acute) - MK-8189 24 mg (Extension)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be treated for a total of 12 weeks. Participants will receive MK-8189-matching placebo QD in the acute treatment period from Week 1-6 followed by MK-8189 24 mg QD in the extension treatment period from Week 7-12 and participants will simultaneously receive risperidone-matching placebo QD from Week 1-12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8189</intervention_name>
    <description>MK-8189 administered QD at a dose of 8 mg, 16 mg, or 24 mg via oral tablet.</description>
    <arm_group_label>MK-8189 16 mg (Acute) - MK-8189 16 mg (Extension)</arm_group_label>
    <arm_group_label>MK-8189 24 mg (Acute) - MK-8189 24 mg (Extension)</arm_group_label>
    <arm_group_label>MK-8189 8 mg (Acute) - MK-8189 8 mg (Extension)</arm_group_label>
    <arm_group_label>Placebo to MK-8189 (Acute) - MK-8189 24 mg (Extension)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>Risperidone administered QD at a dose of 6 mg via oral capsule.</description>
    <arm_group_label>Risperidone 6 mg (Acute) - Risperidone 6 mg (Extension)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to MK-8189</intervention_name>
    <description>MK-8189-matching placebo administered QD via oral tablet.</description>
    <arm_group_label>Placebo to MK-8189 (Acute) - MK-8189 24 mg (Extension)</arm_group_label>
    <arm_group_label>Risperidone 6 mg (Acute) - Risperidone 6 mg (Extension)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to risperidone</intervention_name>
    <description>Risperidone-matching placebo administered QD via oral capsule.</description>
    <arm_group_label>MK-8189 16 mg (Acute) - MK-8189 16 mg (Extension)</arm_group_label>
    <arm_group_label>MK-8189 24 mg (Acute) - MK-8189 24 mg (Extension)</arm_group_label>
    <arm_group_label>MK-8189 8 mg (Acute) - MK-8189 8 mg (Extension)</arm_group_label>
    <arm_group_label>Placebo to MK-8189 (Acute) - MK-8189 24 mg (Extension)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The main inclusion criteria include, but are not limited to the following:&#xD;
&#xD;
          -  Meet the diagnostic criteria for schizophrenia according to the DSM-5&#xD;
&#xD;
          -  Have an illness duration for schizophrenia of at least 1 year and ≤15 years&#xD;
&#xD;
          -  Be confirmed to be experiencing an acute episode of schizophrenia as evidenced by ALL&#xD;
             of the following: (a) onset of the current acute episode is ≤4 weeks prior to&#xD;
             screening (b) current symptoms represent a marked and substantial worsening compared&#xD;
             with the participant's usual symptomatic state prior to the current acute episode, and&#xD;
             are associated with diminished functional ability (c) in need of increased psychiatric&#xD;
             attention to treat worsening acute episode symptoms&#xD;
&#xD;
          -  Have a CGI-S score of ≥4 (moderately ill) at screening and baseline&#xD;
&#xD;
          -  Have an identified responsible person referred to as the &quot;external contact person&quot; who&#xD;
             has agreed to provide information about the participant's location if needed during&#xD;
             outpatient portion of the study. The site personnel must consider this identified&#xD;
             responsible person a reliable contact person, and the contact person must have regular&#xD;
             contact with the participant (defined at screening as direct contact no fewer than 3&#xD;
             times per week), and with the expectation that this frequency of contact would&#xD;
             continue (either in person or via other contact method), throughout duration of the&#xD;
             study, including the follow-up period)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The main exclusion criteria include, but are not limited to the following:&#xD;
&#xD;
          -  Has a primary current diagnosis other than schizophrenia or a comorbid diagnosis that&#xD;
             is primarily responsible for the current symptoms and functional impairment&#xD;
&#xD;
          -  Meets criteria for moderate to severe substance use disorder within past 6 months&#xD;
             prior to screening (excluding those related to caffeine or nicotine)&#xD;
&#xD;
          -  Has a known history of the following: (a) borderline personality disorder, anti-social&#xD;
             personality disorder, or bipolar disorder (b) traumatic brain injury causing ongoing&#xD;
             cognitive difficulties, Alzheimer's disease, or another form of dementia, or any&#xD;
             chronic organic disease of the central nervous system (c) intellectual disability of a&#xD;
             severity that would impact ability to participate in the study&#xD;
&#xD;
          -  Has a current diagnosis of a psychotic disorder other than schizophrenia or a&#xD;
             behavioral disturbance thought to be due to substance abuse&#xD;
&#xD;
          -  Is or was under involuntary commitment for the acute episode, because the participant&#xD;
             is considered a danger to themselves or others&#xD;
&#xD;
          -  Has a history of treatment resistance exhibited by any of the following: (a) no or&#xD;
             minimal response to at least 2 periods of treatment lasting 6 weeks or longer, with&#xD;
             antipsychotic agents at the maximally tolerated dose. Participants who have responded&#xD;
             to antipsychotics only when paired with clozapine are considered treatment resistant&#xD;
             (b) history of electroconvulsive therapy (ECT) treatment for treatment resistant&#xD;
             schizophrenia within the past 5 years (c) past or current use of clozapine as single&#xD;
             or adjunctive therapy for schizophrenia within the past 5 years&#xD;
&#xD;
          -  Is currently participating in or has participated in an interventional clinical&#xD;
             research study within 12 months prior to the screening visit of this current study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Woodland International Research Group, LLC ( Site 1002)</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>501-221-8681</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Woodland Research Northwest, LLC ( Site 1036)</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758-6442</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>479-927-3000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CITRIALS ( Site 1010)</name>
      <address>
        <city>Bellflower</city>
        <state>California</state>
        <zip>90706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>866-478-8391</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Behavioral Research Specialists, LLC ( Site 1032)</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>888-255-5798</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CITRIALS ( Site 1016)</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>866-478-8391</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CNRI - San Diego, LLC ( Site 1034)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>619-481-5252</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research ( Site 1019)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Schuster Medical Research Institute ( Site 1023)</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>818-788-0746</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Behavioral Clinical Research , Inc ( Site 1013)</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>786-570-1971</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fort Lauderdale Behavioral Health Center ( Site 1028)</name>
      <address>
        <city>Oakland Park</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>954-463-4321</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlanta Center For Medical Research ( Site 1022)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>404-881-5800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AMITA Health - St. Elizabeth Campus ( Site 1000)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60622</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>312-491-5498</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital ( Site 1035)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-724-3294</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Altea Research Institute ( Site 1012)</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>702-527-7401</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center ( Site 1033)</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>937-424-1050</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pillar Clinical Research, LLC ( Site 1004)</name>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>75080</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>214-396-4844</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika za psihijatriju Vrapce ( Site 4001)</name>
      <address>
        <city>Zagreb</city>
        <state>Grad Zagreb</state>
        <zip>10090</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>385993542406</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika za psihijatriju Sveti Ivan ( Site 4003)</name>
      <address>
        <city>Zagreb</city>
        <state>Zagrebacka Zupanija</state>
        <zip>10090</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+38513430020</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seishinkai Okehazama Hospital Fujita Kokoro Care Center ( Site 2011)</name>
      <address>
        <city>Toyoake</city>
        <state>Aichi</state>
        <zip>470-1168</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-562-97-1361</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kohnodai Hospital, National Center for Global Health and Medicine ( Site 2005)</name>
      <address>
        <city>Ichikawa</city>
        <state>Chiba</state>
        <zip>272-8516</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-47-372-3501</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wakato Hospital ( Site 2031)</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>808-0139</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-93-742-2000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seimou Hospital ( Site 2004)</name>
      <address>
        <city>Tomioka</city>
        <state>Gunma</state>
        <zip>370-2455</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-274-62-3156</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soushu Hospital ( Site 2008)</name>
      <address>
        <city>Atsugi</city>
        <state>Kanagawa</state>
        <zip>243-0201</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-46-241-3351</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tanzawa Hospital ( Site 2037)</name>
      <address>
        <city>Hadano</city>
        <state>Kanagawa</state>
        <zip>259-1304</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81463882455</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kanagawa Psychiatric Center ( Site 2035)</name>
      <address>
        <city>Yokohama-Shi</city>
        <state>Kanagawa</state>
        <zip>233-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81458220241</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Ryukyu Hospital ( Site 2019)</name>
      <address>
        <city>Kunigamigun</city>
        <state>Okinawa</state>
        <zip>904-1201</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-98-968-2133</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amekudai Hospital ( Site 2020)</name>
      <address>
        <city>Naha</city>
        <state>Okinawa</state>
        <zip>900-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-98-868-2101</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Hizen Psychiatric Medical Center ( Site 2017)</name>
      <address>
        <city>Kanzaki-gun</city>
        <state>Saga</state>
        <zip>842-0192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-952-52-3231</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rainbow and Sea Hospital ( Site 2016)</name>
      <address>
        <city>Karatsu</city>
        <state>Saga</state>
        <zip>847-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-955-77-0711</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ongata Hospital ( Site 2007)</name>
      <address>
        <city>Hachioji</city>
        <state>Tokyo</state>
        <zip>192-0153</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-42-651-3411</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nishigahara Hospital ( Site 2042)</name>
      <address>
        <city>Kita-ku</city>
        <state>Tokyo</state>
        <zip>114-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3917-6561</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Center of Neurology and Psychiatry ( Site 2023)</name>
      <address>
        <city>Kodaira</city>
        <state>Tokyo</state>
        <zip>187-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-42-341-2711</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chiba University Hospital ( Site 2024)</name>
      <address>
        <city>Chiba</city>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-43-222-7171</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inokuchi Noma Hospital ( Site 2030)</name>
      <address>
        <city>Fukuoka</city>
        <zip>815-0074</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-92-551-5301</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kuramitsu Hospital ( Site 2014)</name>
      <address>
        <city>Fukuoka</city>
        <zip>819-0037</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-92-811-1821</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yuge Hospital ( Site 2018)</name>
      <address>
        <city>Kumamoto</city>
        <zip>861-8002</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-96-338-3838</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seijin Hospital ( Site 2026)</name>
      <address>
        <city>Tokyo</city>
        <zip>121-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-50-3734-5401</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Narimasu Kosei Hospital ( Site 2006)</name>
      <address>
        <city>Tokyo</city>
        <zip>175-0091</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3939-1191</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital ( Site 0604)</name>
      <address>
        <city>Busan</city>
        <state>Pusan-Kwangyokshi</state>
        <zip>47392</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82518906436</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital ( Site 0601)</name>
      <address>
        <city>Daegu</city>
        <state>Taegu-Kwangyokshi</state>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82534205747</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital ( Site 0600)</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82220722972</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Daugavpils Psihoneirologiska Slimnica ( Site 8005)</name>
      <address>
        <city>Daugavpils</city>
        <zip>5417</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+371 26558181</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Piejuras Slimnica Psihiatriska Klinika ( Site 8001)</name>
      <address>
        <city>Liepaja</city>
        <zip>3401</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>37128821661</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Specjal. Psychiatryczny ZOZ w Lodzi, Szpital im. Babinskiego ( Site 0905)</name>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <zip>91-229</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48427155985</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arkhangelsk Regional Psychiatric Clinical Hospital ( Site 6020)</name>
      <address>
        <city>Arkhangelsk</city>
        <state>Arkhangel Skaya Oblast</state>
        <zip>163530</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79212464332</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SGHI Leningrad Region Psyconeurology Dispensary ( Site 6017)</name>
      <address>
        <city>Leningrad Region</city>
        <state>Leningradskaya Oblast</state>
        <zip>188820</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79217442120</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lipetsk Regional Psychoneurology Hospital ( Site 6021)</name>
      <address>
        <city>Lipetsk</city>
        <state>Lipetskaya Oblast</state>
        <zip>399083</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74742789515</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moscow Scientific Research Institute for Psychiatry ( Site 6013)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>107076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79036274153</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moscow Scientific Research Institute for Psychiatry ( Site 6016)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>107076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79168216147</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Psychiatric Clinical Hospital 4 named after PB Gannushkin-Psychiatric department 4 ( Site 6023)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>107076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79161277864</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Moscow Regional Clinical Psychiatric Hospital ( Site 6018)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>127083</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79261172088</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bekhterev Research Institute for Psychoneurology ( Site 6008)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>192019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78126700211</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SPb City Psychiatric Hospital #3 na II Skvortsov-Stepanov ( Site 6000)</name>
      <address>
        <city>St. Petersburg</city>
        <state>Sankt-Peterburg</state>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79219456444</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SPb City Psychiatric Hospital #3 na II Skvortsov-Stepanov ( Site 6001)</name>
      <address>
        <city>St. Petersburg</city>
        <state>Sankt-Peterburg</state>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79219700281</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SPb City Psychiatric Hospital #3 na II Skvortsov-Stepanov ( Site 6002)</name>
      <address>
        <city>St. Petersburg</city>
        <state>Sankt-Peterburg</state>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79030951679</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stavropol Region Psychiatric Hospital #2 ( Site 6005)</name>
      <address>
        <city>Stavropol</city>
        <state>Stavropol Skiy Kray</state>
        <zip>357034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78652221395</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Federal State Scientific Institution Research Institute of Mental Health ( Site 6014)</name>
      <address>
        <city>Tomsk</city>
        <state>Tomskaya Oblast</state>
        <zip>634014</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+73822723151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yaroslavl Regional Clinical Psychiatry Hospital ( Site 6022)</name>
      <address>
        <city>Yaroslavl</city>
        <state>Yaroslavskaya Oblast</state>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74852732852</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital ( Site 9006)</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886422052121 x1855</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital ( Site 9001)</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886223123456</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei City Hospital, Songde Branch ( Site 9004)</name>
      <address>
        <city>Taipei</city>
        <zip>110</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886227263141x1263</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital ( Site 9000)</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88628741271</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Linkou Branch ( Site 9002)</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>88633281200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CNE Cherkasy reg. psychiatric hospital of Cherkasy regional council ( Site 7009)</name>
      <address>
        <city>Smila</city>
        <state>Cherkaska Oblast</state>
        <zip>20708</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380964005488</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CNE of Kharkiv Reg. Council Reg. Clinical Psychiatric Hospital Nub 3 ( Site 7012)</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380573418011</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Neurology,Psychiatry and Narcology AMS Ukraine ( Site 7011)</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380577383387</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CNE. Kherson Regional Psychiatric Hospital ( Site 7004)</name>
      <address>
        <city>Kherson</city>
        <state>Khersonska Oblast</state>
        <zip>73488</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380504940457</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyiv City Psychoneurological Hospital 2 ( Site 7008)</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>02192</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380674017623</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CNE Clinical Hospital PSYCHIATRY of executive body of Kyiv City Council -Kyiv City State Admin ( Sit</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>04080</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380503847048</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MNE of KRC-Regional psychiatric and narcological medical association ( Site 7005)</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>08631</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380503847048</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reg. Psych. Hosp. n.a. O. Yuschenko, Dept #21, VNMU n.a. M.Pirogov ( Site 7001)</name>
      <address>
        <city>Vinnytsya</city>
        <state>Vinnytska Oblast</state>
        <zip>21037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380679605672</phone>
    </contact>
  </location>
  <location_countries>
    <country>Croatia</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

